Newly Identified Hormone May Be Critical Driver of Type 1 and Type 2 Diabetes

A newly discovered hormone named fabkin helps regulate metabolism and may play an important role in the development of both type 1 and type 2 diabetes, according to research led by the Sabri Ülker Center for Metabolic Research at Harvard T.H. Chan School of Public Health. The findings were published in Nature.

The study showed blood levels of fabkin were abnormally high in mice and human patients with either type 1 or type 2 diabetes. Researchers led by Gokhan S. Hotamisligil, MD, PhD, director of the Sabri Ülker Center, found that blocking the activity of fabkin prevented the development of both forms of diabetes in the animals. Fabkin likely plays a similar role in humans and the hormone complex could be a promising therapeutic target, according to the researchers. 

Fabkin is different from traditional hormones in that it is not a single molecule with a single defined receptor. Instead, fabkin is composed of a functional protein complex consisting of multiple proteins, including fatty acid binding protein 4 (FABP4), adenosine kinase (ADK) and nucleoside diphosphate kinase (NDPK). Through a series of experiments, the researchers determined that fabkin regulates energy signals outside of cells. These signals then act through a family of receptors to control target cell function. In the case of diabetes, fabkin controls the function of beta cells in the pancreas that are responsible for insulin production. 

More than a decade ago, Hotamisligil and colleagues discovered that a protein known as FABP4 is secreted from fat cells during lipolysis, the process in which lipids stored within fat cells are broken down, typically in response to starvation. Numerous studies have since shown correlations between circulating FABP4 and metabolic diseases including obesity, diabetes, cardiovascular disease, and cancer. However, the mechanism of action was unknown. 

In the new study, the researchers showed that when FABP4 is secreted from fat cells and enters the blood stream, it binds with the enzymes NDPK and ADK to form the protein complex now identified as fabkin. In this protein complex, FABP4 modifies the activity of NDPK and ADK to regulate levels of molecules known as ATP and ADP, which are the essential units of energy in biology. The researchers discovered that surface receptors on nearby cells sense the changing ratio of ATP to ADP, triggering the cells to respond to the changing energy status. As such, fabkin is able to regulate the function of these target cells.  

The authors showed that the insulin-producing beta cells of the pancreas are a target of fabkin and that the hormone is a driving force behind the development of diabetes. When the researchers used an antibody to neutralize fabkin in mice, the animals did not develop diabetes. When the antibody was given to obese, diabetic mice, they reverted to a healthy state. 

You may also like

  • Islets in the Stream: Could Stem Cell Technology Be an Eventual Cure for Type 1 Diabetes?

    Recent studies have shown how stem cell-derived therapies have the potential as a renewable source of insulin-producing pancreatic islet cells. Promising as these results are, could stem cell technology eventually lead to a cure for diabetes as well as impacts well beyond endocrinology? Last December, two papers appeared in Cell Stem Cell and Cell Reports…

  • People with Diabetes and Cognitive Decline May Be at Higher Risk for Heart Disease

    People with type 2 diabetes who have cognitive impairment could be at greater risk for stroke, heart attack, or death than other individuals with diabetes, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism. Cognitive impairment is when a person has trouble remembering, learning new things, concentrating, or making…